Animal models of primary biliary cirrhosis

Seminars in Liver Disease

Volumn 34, Issue 3, 2014, Pages 285-296

  Wang, Jinjun ^a,b   Yang, Guo Xiang ^a   Tsuneyama, Koichi ^c   Gershwin, M Eric ^a   Ridgway, William M ^d   Leung, Patrick S C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YANGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF TOYAMA   (Japan)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

antimitochondrial antibodies; cholangiocytes; dnTGFBRII; intrahepatic bile ducts; microbial immunization; NOD.ABD; xenobiotics

Indexed keywords

AUTOANTIBODY; CD1D ANTIGEN; CD20 ANTIBODY; CD79 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; MITOCHONDRION ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; URSODEOXYCHOLIC ACID; XENOBIOTIC AGENT; BIOLOGICAL MARKER; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNITY; BILE DUCT DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLANGITIS; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; ENVIRONMENTAL IMPACT; ESCHERICHIA COLI; GENETIC PREDISPOSITION; GRANULOMA; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOPATHOLOGY; INNATE IMMUNITY; LIVER TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER T CELL; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STREPTOCOCCUS INTERMEDIUS; ANIMAL; BILIARY CIRRHOSIS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; METABOLISM; MICROBIOLOGY; NONOBESE DIABETIC MOUSE; PATHOGENICITY; PATHOLOGY; SPHINGOMONADACEAE; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNITY; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; HUMANS; LIVER CIRRHOSIS, BILIARY; MICE, INBRED NOD; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SPHINGOMONADACEAE; XENOBIOTICS;

EID: 84905036457     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1383728     Document Type: Article

References (102)

1. Liu Y., Meyer C., Xu C., et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol: 2013; 304 5 G449 G468
2. Gershwin M. E., Ansari A. A., Mackay I. R., et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev: 2000; 174 210 225
3. Leung P. S., Chuang D. T., Wynn R. M., et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology: 1995; 22 2 505 513
4. Moteki S., Leung P. S., Dickson E. R., et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology: 1996; 23 3 436 444
5. Van de Water J., Ansari A., Prindiville T., et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med: 1995; 181 2 723 733
6. Gershwin M. E., Mackay I. R., Sturgess A., Coppel R. L. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol: 1987; 138 10 3525 3531
7. You Z., Wang Q., Bian Z., et al. The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun: 2012; 39 3 216 221
8. Ishibashi H., Shimoda S., Gershwin M. E. The immune response to mitochondrial autoantigens. Semin Liver Dis: 2005; 25 3 337 346
9. Chuang Y. H., Ridgway W. M., Ueno Y., Gershwin M. E. Animal models of primary biliary cirrhosis. Clin Liver Dis: 2008; 12 2 333 347, ix ix
10. Gershwin M. E., Mackay I. R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology: 2008; 47 2 737 745
11. Leung P. S., Coppel R. L., Gershwin M. E. Etiology of primary biliary cirrhosis: the search for the culprit. Semin Liver Dis: 2005; 25 3 327 336
12. Dhirapong A., Lleo A., Yang G. X., et al. B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology: 2011; 53 2 527 535
13. Lleo A., Bowlus C. L., Yang G. X., et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology: 2010; 52 3 987 998
14. Oertelt S., Rieger R., Selmi C., et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology: 2007; 45 3 659 665
15. Folci M., Meda F., Gershwin M. E., Selmi C. Cutting-edge issues in primary biliary cirrhosis. Clin Rev Allergy Immunol: 2012; 42 3 342 354
16. Ali F., Rowley M., Jayakrishnan B., Teuber S., Gershwin M. E., Mackay I. R. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. J Autoimmun: 2011; 37 2 79 87
17. Jin Q., Moritoki Y., Lleo A., et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology: 2012; 55 5 1495 1506
18. Lleo A., Liao J., Invernizzi P., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology: 2012; 55 1 153 160
19. Persani L., Bonomi M., Lleo A., et al. Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. J Autoimmun: 2012; 38 2-3 J193 J196
20. Rong G., Zhong R., Lleo A., et al. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology: 2011; 54 1 196 203
21. Takahashi T., Miura T., Nakamura J., et al. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology: 2012; 55 3 846 855
22. Wang Q., Selmi C., Zhou X., et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun: 2013; 41 140 145
23. Zhang W., Ono Y., Miyamura Y., Bowlus C. L., Gershwin M. E., Maverakis E. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun: 2011; 37 2 71 78
24. Kawata K., Tsuda M., Yang G. X., et al. Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis. PLoS ONE: 2013; 8 9 e74225
25. Kawata K., Yang G. X., Ando Y., et al. Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFβRII mice. Hepatology: 2013; 58 3 1094 1104
26. Ando Y., Yang G. X., Kenny T. P., et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun: 2013; 41 111 119
27. Dhirapong A., Yang G. X., Nadler S., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology: 2013; 57 2 708 715
28. Kikutani H., Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol: 1992; 51 285 322
29. Chen Y. G., Scheuplein F., Osborne M. A., Tsaih S. W., Chapman H. D., Serreze D. V. Idd9/11 genetic locus regulates diabetogenic activity of CD4 T-cells in nonobese diabetic (NOD) mice. Diabetes: 2008; 57 12 3273 3280
30. Fox C. J., Paterson A. D., Mortin-Toth S. M., Danska J. S. Two genetic loci regulate T cell-dependent islet inflammation and drive autoimmune diabetes pathogenesis. Am J Hum Genet: 2000; 67 1 67 81
31. Fraser H. I., Dendrou C. A., Healy B., et al. Nonobese diabetic congenic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene. J Immunol: 2010; 184 9 5075 5084
32. Aoki C. A., Borchers A. T., Ridgway W. M., Keen C. L., Ansari A. A., Gershwin M. E. NOD mice and autoimmunity. Autoimmun Rev: 2005; 4 6 373 379
33. Koarada S., Wu Y., Fertig N., et al. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol: 2004; 173 4 2315 2323
34. Irie J., Wu Y., Wicker L. S., et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med: 2006; 203 5 1209 1219
35. Yang G. X., Wu Y., Tsukamoto H., et al. CD8 T cells mediate direct biliary ductule damage in nonobese diabetic autoimmune biliary disease. J Immunol: 2011; 186 2 1259 1267
36. Taylor A. W. Review of the activation of TGF-beta in immunity. J Leukoc Biol: 2009; 85 1 29 33
37. Yoshimura A., Wakabayashi Y., Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem: 2010; 147 6 781 792
38. Ebert E. C., Panja A., Das K. M., et al. Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol: 2009; 155 1 65 71
39. Kel J. M., Girard-Madoux M. J., Reizis B., Clausen B. E. TGF-beta is required to maintain the pool of immature Langerhans cells in the epidermis. J Immunol: 2010; 185 6 3248 3255
40. Perruche S., Zhang P., Maruyama T., Bluestone J. A., Saas P., Chen W. Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol: 2009; 183 2 953 961
41. Oertelt S., Lian Z. X., Cheng C. M., et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol: 2006; 177 3 1655 1660
42. Gorelik L., Flavell R. A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity: 2000; 12 2 171 181
43. Chuang Y. H., Lian Z. X., Yang G. X., et al. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology: 2008; 47 2 571 580
44. Yang C. Y., Leung P. S., Yang G. X., et al. Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol: 2012; 168 3 261 267
45. Invernizzi P., Crosignani A., Battezzati P. M., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology: 1997; 25 5 1090 1095
46. Kim W. R., Poterucha J. J., Jorgensen R. A., et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology: 1997; 26 1 22 26
47. Moritoki Y., Lian Z. X., Lindor K., et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology: 2009; 50 6 1893 1903
48. Chuang Y. H., Lian Z. X., Tsuneyama K., et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun: 2006; 26 4 232 240
49. Yoshida K., Yang G. X., Zhang W., et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology: 2009; 50 5 1494 1500
50. Tsuda M., Zhang W., Yang G. X., et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology: 2013; 57 2 806 816
51. Ando Y., Yang G. X., Tsuda M., et al. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology: 2012; 56 4 1418 1426
52. Nakamura A., Yamazaki K., Suzuki K., Sato S. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol: 1997; 92 12 2245 2249
53. Lan R. Y., Cheng C., Lian Z. X., et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology: 2006; 43 4 729 737
54. Shimoda S., Nakamura M., Ishibashi H., Hayashida K., Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med: 1995; 181 5 1835 1845
55. Shimoda S., Van de Water J., Ansari A., et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest: 1998; 102 10 1831 1840
56. Bogdanos D. P., Baum H., Grasso A., et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol: 2004; 40 1 31 39
57. Bogdanos D. P., Baum H., Okamoto M., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology: 2005; 42 2 458 465
58. Bogdanos D. P., Baum H., Sharma U. C., et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol: 2002; 36 1 14 21
59. Bogdanos D. P., Koutsoumpas A., Baum H., Vergani D. Borrelia Burgdorferi: a new self-mimicking trigger in primary biliary cirrhosis. Dig Liver Dis: 2006; 38 10 781 782, author reply 782-783
60. Shimoda S., Nakamura M., Shigematsu H., et al. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology: 2000; 31 6 1212 1216
61. Burroughs A. K., Butler P., Sternberg M. J., Baum H. Molecular mimicry in liver disease. Nature: 1992; 358 6385 377 378
62. Selmi C., Balkwill D. L., Invernizzi P., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology: 2003; 38 5 1250 1257
63. Abdulkarim A. S., Petrovic L. M., Kim W. R., Angulo P., Lloyd R. V., Lindor K. D. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae ? J Hepatol: 2004; 40 3 380 384
64. Kita H., Matsumura S., He X. S., et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest: 2002; 109 9 1231 1240
65. Liu H., Norman G. L., Shums Z., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun: 2010; 35 4 436 442
66. Wang J., Budamagunta M. S., Voss J. C., et al. Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. J Immunol: 2013; 191 5 2126 2133
67. Hirschfield G. M., Gershwin M. E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol: 2013; 8 303 330
68. Benson G. D., Kikuchi K., Miyakawa H., Tanaka A., Watnik M. R., Gershwin M. E. Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clin Dev Immunol: 2004; 11 2 129 133
69. Long S. A., Quan C., Van de Water J., et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol: 2001; 167 5 2956 2963
70. Rieger R., Leung P. S., Jeddeloh M. R., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun: 2006; 27 1 7 16
71. Leung P. S., Lam K., Kurth M. J., Coppel R. L., Gershwin M. E. Xenobiotics and autoimmunity: does acetaminophen cause primary biliary cirrhosis? Trends Mol Med: 2012; 18 10 577 582
72. Naiyanetr P., Butler J. D., Meng L., et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J Autoimmun: 2011; 37 3 209 216
73. Leung P. S., Wang J., Naiyanetr P., et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun: 2013; 41 79 86
74. Amano K., Leung P. S., Rieger R., et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol: 2005; 174 9 5874 5883
75. Wakabayashi K., Lian Z. X., Leung P. S., et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology: 2008; 48 2 531 540
76. Wakabayashi K., Yoshida K., Leung P. S., et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol: 2009; 155 3 577 586
77. Selmi C., Leung P. S., Sherr D. H., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun: 2012; 39 4 272 284
78. Bogdanos D. P., Smyk D. S., Rigopoulou E. I., et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun: 2012; 38 2-3 J156 J169
79. Shoenfeld Y., Tincani A., Gershwin M. E. Sex gender and autoimmunity. J Autoimmun: 2012; 38 2-3 J71 J73
80. Wu S. J., Yang Y. H., Tsuneyama K., et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology: 2011; 53 3 915 925
81. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M. E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev: 2010; 9 5 A259 A266
82. Takeuchi M., Hamana K., Hiraishi A. Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses. Int J Syst Evol Microbiol: 2001; 51 Pt 4 1405 1417
83. Padgett K. A., Selmi C., Kenny T. P., et al. Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J Autoimmun: 2005; 24 3 209 219
84. Brodie E. L., DeSantis T. Z., Parker J. P., Zubietta I. X., Piceno Y. M., Andersen G. L. Urban aerosols harbor diverse and dynamic bacterial populations. Proc Natl Acad Sci U S A: 2007; 104 1 299 304
85. Cavicchioli R., Fegatella F., Ostrowski M., Eguchi M., Gottschal J. Sphingomonads from marine environments. J Ind Microbiol Biotechnol: 1999; 23 4-5 268 272
86. Kaplan M. M. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol: 2004; 99 11 2147 2149
87. Olafsson S., Gudjonsson H., Selmi C., et al. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. Am J Gastroenterol: 2004; 99 11 2143 2146
88. Kawahara K., Moll H., Knirel Y. A., Seydel U., Zähringer U. Structural analysis of two glycosphingolipids from the lipopolysaccharide- lacking bacterium Sphingomonas capsulata. Eur J Biochem: 2000; 267 6 1837 1846
89. Kosako Y., Yabuuchi E., Naka T., Fujiwara N., Kobayashi K. Proposal of Sphingomonadaceae fam. nov., consisting of Sphingomonas Yabuuchi et al. 1990, Erythrobacter Shiba and Shimidu 1982, Erythromicrobium Yurkov et al. 1994, Porphyrobacter Fuerst et al. 1993, Zymomonas Kluyver and van Niel 1936, and Sandaracinobacter Yurkov et al. 1997, with the type genus Sphingomonas Yabuuchi et al. 1990. Microbiol Immunol: 2000; 44 7 563 575
90. Kinjo Y., Wu D., Kim G., et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature: 2005; 434 7032 520 525
91. Mattner J., Debord K. L., Ismail N., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature: 2005; 434 7032 525 529
92. Mattner J., Savage P. B., Leung P., et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe: 2008; 3 5 304 315
93. Lyons P. A., Hancock W. W., Denny P., et al. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity: 2000; 13 1 107 115
94. Wicker L. S., Leiter E. H., Todd J. A., et al. Beta 2-microglobulin- deficient NOD mice do not develop insulitis or diabetes. Diabetes: 1994; 43 3 500 504
95. Koarada S., Wu Y., Yim Y. S., Wakeland E. W., Ridgway W. M. Nonobese diabetic CD4 lymphocytosis maps outside the MHC locus on chromosome 17. Immunogenetics: 2004; 56 5 333 337
96. Podolin P. L., Denny P., Armitage N., et al. Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3. Mamm Genome: 1998; 9 4 283 286
97. Wang J., Yang G. X., Zhang W., et al. Escherichia coli infection induces autoimmune cholangitis and antimitochondrial antibodies in. non-obese diabetic (NOD).B6 (Idd10/Idd18) mice. Clin Exp Immunol: 2014; 175 2 192 201
98. Mohammed J. P., Fusakio M. E., Rainbow D. B., et al. Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans -induced liver autoimmunity. J Immunol: 2011; 187 1 337 349
99. Haruta I., Kikuchi K., Hashimoto E., et al. Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation. Lab Invest: 2010; 90 4 577 588
100. Haruta I., Kikuchi K., Nakamura M., et al. Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis. J Clin Immunol: 2012; 32 5 1026 1037
101. Gershwin M. E., Leung P. S., Ridgway W. M., Coppel R. L., Ansari A. A. Reply: To PMID 22996325. Hepatology: 2013; 58 2 830
102. Lleo A., Oertelt-Prigione S., Bianchi I., et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun: 2013; 41 87 91